Protein Farnesylation Inhibitors Cause Donut-shaped Cell Nuclei Attributable to a Centrosome Separation Defect

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2011 Mar 9

PMID 21383178

Citations 50

Authors

Valerie L R M Verstraeten

Lana A Peckham

Michelle Olive

Brian C Capell

Francis S Collins

Elizabeth G Nabel

Stephen G Young

Loren G Fong

Jan Lammerding

Affiliations

Soon will be listed here.

Abstract

Despite the success of protein farnesyltransferase inhibitors (FTIs) in the treatment of certain malignancies, their mode of action is incompletely understood. Dissecting the molecular pathways affected by FTIs is important, particularly because this group of drugs is now being tested for the treatment of Hutchinson-Gilford progeria syndrome. In the current study, we show that FTI treatment causes a centrosome separation defect, leading to the formation of donut-shaped nuclei in nontransformed cell lines, tumor cell lines, and tissues of FTI-treated mice. Donut-shaped nuclei arise during chromatin decondensation in late mitosis; subsequently, cells with donut-shaped nuclei exhibit defects in karyokinesis, develop aneuploidy, and are often binucleated. Binucleated cells proliferate slowly. We identified lamin B1 and proteasome-mediated degradation of pericentrin as critical components in FTI-induced "donut formation" and binucleation. Reducing pericentrin expression or ectopic expression of nonfarnesylated lamin B1 was sufficient to elicit donut formation and binucleated cells, whereas blocking proteasomal degradation eliminated FTI-induced donut formation. Our studies have uncovered an important role of FTIs on centrosome separation and define pericentrin as a (indirect) target of FTIs affecting centrosome position and bipolar spindle formation, likely explaining some of the anticancer effects of these drugs.

Citing Articles

Nuclear stiffness through lamin A/C overexpression differentially modulates chromosomal instability biomarkers.

Bosch-Calvet M, Perez-Venteo A, Cebria-Xart A, Garcia-Cajide M, Mauvezin C Biol Cell. 2025; 117(2):e12001.

PMID: 40012191 PMC: 11865694. DOI: 10.1111/boc.12001.

The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice.

Muela-Zarzuela I, Suarez-Rivero J, Boy-Ruiz D, Lopez-Perez J, Sotelo-Montoro M, Del Mar Navarrete-Alonso M Aging Cell. 2024; 23(9):e14272.

PMID: 39192596 PMC: 11488313. DOI: 10.1111/acel.14272.

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.

Odinammadu K, Shilagardi K, Tuminelli K, Judge D, Gordon L, Michaelis S Nucleus. 2023; 14(1):2288476.

PMID: 38050983 PMC: 10730222. DOI: 10.1080/19491034.2023.2288476.

Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS.

Kim B, Chung Y, Woo T, Kang S, Park S, Park B Cells. 2023; 12(18).

PMID: 37759521 PMC: 10527460. DOI: 10.3390/cells12182299.

Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.

Hartinger R, Lederer E, Schena E, Lattanzi G, Djabali K Cells. 2023; 12(10).

PMID: 37408186 PMC: 10216179. DOI: 10.3390/cells12101350.

References

Tsai M, Wang S, Heidinger J, Shumaker D, Adam S, Goldman R . A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science. 2006; 311(5769):1887-93. DOI: 10.1126/science.1122771. View

Crespo N, Delarue F, Ohkanda J, Carrico D, Hamilton A, Sebti S . The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ. 2002; 9(7):702-9. DOI: 10.1038/sj.cdd.4401023. View

Rauch A, Thiel C, Schindler D, Wick U, Crow Y, Ekici A . Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science. 2008; 319(5864):816-9. DOI: 10.1126/science.1151174. View

Sinensky M, Beck L, Leonard S, Evans R . Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem. 1990; 265(32):19937-41. View

Capell B, Olive M, Erdos M, Cao K, Faddah D, Tavarez U . A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A. 2008; 105(41):15902-7. PMC: 2562418. DOI: 10.1073/pnas.0807840105. View

Yang S, Meta M, Qiao X, Frost D, Bauch J, Coffinier C . A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest. 2006; 116(8):2115-21. PMC: 1513052. DOI: 10.1172/JCI28968. View

Moynihan K, Pooley R, Miller P, Kaverina I, Bader D . Murine CENP-F regulates centrosomal microtubule nucleation and interacts with Hook2 at the centrosome. Mol Biol Cell. 2009; 20(22):4790-803. PMC: 2777108. DOI: 10.1091/mbc.e09-07-0560. View

Yang S, Andres D, Spielmann H, Young S, Fong L . Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest. 2008; 118(10):3291-300. PMC: 2525700. DOI: 10.1172/JCI35876. View

Kim J, Choi Y, Vallentin A, Hunrichs B, Hellerstein M, Peehl D . Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008; 68(16):6831-9. PMC: 2597632. DOI: 10.1158/0008-5472.CAN-07-6195. View

10.

Ashar H, James L, Gray K, Carr D, Black S, Armstrong L . Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000; 275(39):30451-7. DOI: 10.1074/jbc.M003469200. View

11.

Meta M, Yang S, Bergo M, Fong L, Young S . Protein farnesyltransferase inhibitors and progeria. Trends Mol Med. 2006; 12(10):480-7. DOI: 10.1016/j.molmed.2006.08.006. View

12.

Davies B, Barnes 2nd R, Tu Y, Ren S, Andres D, Spielmann H . An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet. 2010; 19(13):2682-94. PMC: 2883346. DOI: 10.1093/hmg/ddq158. View

13.

Fong L, Ng J, Lammerding J, Vickers T, Meta M, Cote N . Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest. 2006; 116(3):743-52. PMC: 1386109. DOI: 10.1172/JCI27125. View

14.

Goodman B, Channels W, Qiu M, Iglesias P, Yang G, Zheng Y . Lamin B counteracts the kinesin Eg5 to restrain spindle pole separation during spindle assembly. J Biol Chem. 2010; 285(45):35238-44. PMC: 2966137. DOI: 10.1074/jbc.M110.140749. View

15.

Sebti S, Der C . Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer. 2004; 3(12):945-51. DOI: 10.1038/nrc1234. View

16.

Putkey F, Cramer T, Morphew M, Silk A, Johnson R, McIntosh J . Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell. 2002; 3(3):351-65. DOI: 10.1016/s1534-5807(02)00255-1. View

17.

Crespo N, Ohkanda J, Yen T, Hamilton A, Sebti S . The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001; 276(19):16161-7. DOI: 10.1074/jbc.M006213200. View

18.

Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota F, Eisenhaber F . Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol. 2007; 3(4):e66. PMC: 1847700. DOI: 10.1371/journal.pcbi.0030066. View

19.

Lamson M, Phillips G, Shen J, Lukacsko P, Friedhoff L, Niecestro R . Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos. 2002; 23(4):143-9. DOI: 10.1002/bdd.304. View

20.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View